Akacid-medical-formulation, a novel biocidal oligoguanidine with antitumor activity reduces S-phase in prostate cancer cell lines through the Erk 1/2 mitogen-activated protein kinase pathway

  • Authors:
    • Hannes Neuwirt
    • Hansgeorg Muller
    • Ilaria T.R. Cavarretta
    • Martin Tiefenthaler
    • Georg Bartsch
    • Guenther Konwalinka
    • Zoran Culig
  • View Affiliations

  • Published online on: August 1, 2006     https://doi.org/10.3892/ijo.29.2.503
  • Pages: 503-512
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Oligomeric guanidines are highly efficient biocides against a broad spectrum of microorganisms. However, their antitumor effects have not been studied so far. We investigated an antiproliferative effect of Akacid-medical-formulation (AMF), a member of the oligoguanidine family of biocides, against solid cancer cell lines and primary cells by measuring [3H]-thymidine incorporation. Additionally, we examined cell cycle distribution in two AMF-sensitive prostate cancer cell lines (DU-145, LNCaP) using flow cytometry. Finally, the influence of AMF on cell cycle regulatory molecules and intracellular kinase cascade-related signaling molecules was assessed. We found that AMF has variable antiproliferative effects on all tested cells. In DU-145 and LNCaP cells, flow cytometric studies showed a reduction of S-phase with a maximum extent of 24 and 58%, respectively. This was associated with a decrease in expression of cyclin D1, cyclin-dependent kinases 2 and 4, while having varying effects on expression of cyclin E and p27. Additionally, reduced phosphorylation of Erk1 and Erk2 was found, whereas expression of phospho-Akt1 remained unchanged. Herein we report for the first time that AMF exerts potent antiproliferative activity against various malignant cell lines, including those of prostate. We therefore recommend further investigation of the anticancer activity of this biocidal oliguanidine.

Related Articles

Journal Cover

August 2006
Volume 29 Issue 2

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Neuwirt H, Muller H, Cavarretta IT, Tiefenthaler M, Bartsch G, Konwalinka G and Culig Z: Akacid-medical-formulation, a novel biocidal oligoguanidine with antitumor activity reduces S-phase in prostate cancer cell lines through the Erk 1/2 mitogen-activated protein kinase pathway. Int J Oncol 29: 503-512, 2006
APA
Neuwirt, H., Muller, H., Cavarretta, I.T., Tiefenthaler, M., Bartsch, G., Konwalinka, G., & Culig, Z. (2006). Akacid-medical-formulation, a novel biocidal oligoguanidine with antitumor activity reduces S-phase in prostate cancer cell lines through the Erk 1/2 mitogen-activated protein kinase pathway. International Journal of Oncology, 29, 503-512. https://doi.org/10.3892/ijo.29.2.503
MLA
Neuwirt, H., Muller, H., Cavarretta, I. T., Tiefenthaler, M., Bartsch, G., Konwalinka, G., Culig, Z."Akacid-medical-formulation, a novel biocidal oligoguanidine with antitumor activity reduces S-phase in prostate cancer cell lines through the Erk 1/2 mitogen-activated protein kinase pathway". International Journal of Oncology 29.2 (2006): 503-512.
Chicago
Neuwirt, H., Muller, H., Cavarretta, I. T., Tiefenthaler, M., Bartsch, G., Konwalinka, G., Culig, Z."Akacid-medical-formulation, a novel biocidal oligoguanidine with antitumor activity reduces S-phase in prostate cancer cell lines through the Erk 1/2 mitogen-activated protein kinase pathway". International Journal of Oncology 29, no. 2 (2006): 503-512. https://doi.org/10.3892/ijo.29.2.503